Pattern Recognition_Blackstone

Pattern Recognition

Insights from the World’s Leading Alternative Asset Manager

March 14, 2025

Real Estate: The Power of Skilled Investing

By Joe Zidle
  • Historically, some of the best returns came when investors least expected them.
  • In the five years following both the Global Financial Crisis and Savings & Loan Crisis, private real estate saw returns 2x greater than the long-term average excluding these recovery periods.
  • Missing out on investing during these recovery periods means potentially missing some of the top performing vintage years – these are the times to consider leaning in, not sitting out.
Returns Post-GFC and S&L Periods
Private Real Estate Annualized Average Returns

Source: NCREIF, as of June 30, 2024. Reflects the NFI-ODCE levered gross total return. Long-term average excluding 5-year recovery periods reflects annualized average 5-year returns from June 30, 1993 to June 30, 2024, excluding the 5 years following the Savings and Loan Crisis (“S&L”) (starting June 30, 1993) and Global Financial Crisis (“GFC”) (starting December 30, 2009). 5-year recovery periods post real estate downturns reflect the average of annualized 5-year returns following the Savings and Loan Crisis and the Global Financial Crisis.


February 28, 2025

Closing the Medical Innovation Funding Gap

By David Stubbs
  • Genomics, engineering and AI are advancing innovation in life sciences at an unprecedented pace, leading to the invention of many more potential medicines and medical devices than ever before.
  • Despite this progress, product development remains prohibitively expensive – averaging $2.6 billion per new medicine.1
  • 1 in 3 new therapies remain unfunded due to an estimated $172 billion annual funding gap.
  • We are helping to close this gap by collaborating with premier biopharma companies to fund breakthrough medicines and medical technologies, allowing them to reach patients who need them.
Annual Biopharma R&D Funding Gap
R&D Capital

Source: Evaluate Pharma and Morgan Stanley, as of January 2024. The annual funding gap is Blackstone’s estimate of the gap between the annual spread between the demand for medicine and device development capital and the supply of development capital from Biopharma and MedTech companies through R&D budgets.

1. Deloitte Analysis, 2022.


February 26, 2025

60/40 Portfolio Is Losing its Edge

By Joe Zidle
  • The classic 60/40 stock and bond mix has been a go-to for growth and stability.
  • But since 2022, stocks and bonds have been moving in sync – only displaying a negative correlation 19% of the time. 
  • With bonds failing to hedge against stock downturns, we believe this strategy is becoming unreliable. 
  • In our view, this creates an opportunity for investors to rethink diversification and increase exposure to private markets. 
Stock-Bond Correlation from 2022 to Present
(% of the time)

Source: Bloomberg, as of 1/31/2025. Based on monthly returns from January 2022 to January 2025 between the S&P 500 Index (stocks) and Bloomberg US Treasury Index (bonds).


Stay up-to-date

Sign up for Blackstone Market Commentary and Pattern Recognition updates.


Opinions expressed reflect the current opinions of Blackstone as of the date of publishing only and are based on Blackstone’s opinions of the then-current market environment, which is subject to change. Certain information contained in the content discusses general market activity, industry or sector trends, or other broad-based economic, market or political conditions and should not be construed as research or investment advice.

Certain information and data provided in this content are based on Blackstone proprietary knowledge and data. Portfolio companies may provide proprietary market data to Blackstone, including about local market supply and demand conditions, current market rents and operating expenses, capital expenditures, and valuations for multiple assets. Such proprietary market data is used by Blackstone to evaluate market trends as well as to underwrite potential and existing investments. Additionally, certain information contained in this content has been obtained from portfolio companies and/or sources outside Blackstone, such as press releases, reports, websites, and/or articles, which in certain cases have not been updated through the date hereof. While such information is believed to be reliable for purposes used herein, no representations are made as to the accuracy or completeness thereof and none of Blackstone, its funds, nor any of their affiliates takes any responsibility for, and has not independently verified, any such information. There can be no assurances that any of the trends described herein will continue or will not reverse. Past events and trends do not imply, predict or guarantee, and are not necessarily indicative of, future events or results. 

This commentary does not constitute an offer to sell any securities or the solicitation of an offer to purchase any securities. This commentary discusses broad market, industry or sector trends, or other general economic, market or political conditions and has not been provided in a fiduciary capacity under ERISA and should not be construed as research, investment advice, or any investment recommendation. Past performance is not necessarily indicative of future performance.